{"title":"Clinical features and treatment outcomes of progressive uveal melanoma.","authors":"Milda Rancelyte, Justinas Pamedys, Ruta Grigiene, Birute Brasiuniene","doi":"10.22551/2023.39.1002.10251","DOIUrl":"https://doi.org/10.22551/2023.39.1002.10251","url":null,"abstract":"<p><p>Uveal melanoma (UM) is a rare malignant tumor that differs from cutaneous melanoma in terms of pathogenesis, clinical behavior, and treatment response. Despite treatment for the primary tumor, 50% of UM patients develop metastatic disease, with the liver being the most affected organ. Furthermore, UM responds poorly to chemotherapy and immune checkpoint inhibitors. We present a clinical case of a 58-year-old female patient who was diagnosed with right eye choroidal melanoma cT2aN0M0. For the treatment of the initial tumor, the patient received stereotactic radiotherapy. However, 11 months after the initial diagnosis, the disease had progressed to the liver. The patient underwent radiofrequency ablation of liver metastases, then as the UM progressed - anti-PD-1 immunotherapy with nivolumab and ipilimumab were prescribed for the first-line palliative systemic treatment, later chemotherapy with dacarbazine (5 cycles) as the second-line systemic treatment. Based on the Foundation-One®CDx findings and an overview of clinical trials data, the MEK inhibitor trametinib was prescribed as a third-line palliative treatment. The patient died due to cancerous intoxication, with overall survival (OS) of 28 months (∼2.33 years) and a progression-free survival (PFS) of 11 months (∼0.92 years) since the initial diagnosis. Treatment-related adverse events could have an impact on the general health condition of the patient.</p>","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"10 2","pages":"102-106"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/eb/acc-10-10251.PMC10289051.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9705171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archive of clinical casesPub Date : 2022-12-20eCollection Date: 2024-01-01DOI: 10.22551/2024.45.1104.10303
Catrinel-Ana Codău, Flavia Coman, Bogdan Novac
{"title":"Challenging management of coralliform kidney and ureteral stones.","authors":"Catrinel-Ana Codău, Flavia Coman, Bogdan Novac","doi":"10.22551/2024.45.1104.10303","DOIUrl":"https://doi.org/10.22551/2024.45.1104.10303","url":null,"abstract":"<p><p>Coralliform kidney stones represent a severe form of nephrolithiasis, posing significant challenges due to their size and associated complications, such as recurrent infections and renal impairment. We present the case of a 34-year-old female with chronic venous disease, anemia, and recurrent <i>Escherichia coli</i> urinary tract infections, who was diagnosed with a right-sided coralliform renal calculus and a ureteral pelvic stone. The management included semi-rigid ureteroscopy with laser lithotripsy for the ureteral stone, percutaneous nephrolithotomy (PCNL) for the coralliform stone, and placement of a ureteral stent. Despite anatomical challenges during PCNL, residual stones were addressed via staged extracorporeal shock wave lithotripsy. This case highlights the complexity of surgical management in advanced nephrolithiasis and the necessity for a multidisciplinary approach.</p>","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"11 4","pages":"127-131"},"PeriodicalIF":0.8,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archive of clinical casesPub Date : 2022-07-07eCollection Date: 2022-01-01DOI: 10.22551/2022.35.0902.10206
Toktam Alirezaei, Mohammad Kalateh Agha Mohammadi, Rana Irilouzadian, Hamidreza Zarinparsa
{"title":"Marijuana-induced myocarditis in a 24-year-old man.","authors":"Toktam Alirezaei, Mohammad Kalateh Agha Mohammadi, Rana Irilouzadian, Hamidreza Zarinparsa","doi":"10.22551/2022.35.0902.10206","DOIUrl":"10.22551/2022.35.0902.10206","url":null,"abstract":"<p><p>As marijuana, the most widely-used illicit drug in adolescents and adults, has some unknown side effects, marijuana abuse has become a public health concern. Also, marijuana affects different organs such as heart in its rate, rhythm and coronary flow; it eventually leads to events such as myocardial infarction and rarely myocarditis. A 24-year-old man without any medical history or cardiovascular risk factors presented with chest pain after marijuana consumption. Based on electrocardiogram, myocardial cytolysis and transthoracic echocardiography acute myocarditis diagnosis was established. A few days later, transthoracic echocardiography showed a small clot in apex with reduced left ventricle ejection fraction, in the absence of local akinesia. The patient was discharged with oral anticoagulant stable and without any symptoms. The myocarditis after marijuana abuse is rare. The physicians should include acute myocarditis in differential diagnosis of a patient with chest pain after using marijuana.</p>","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"9 2","pages":"69-74"},"PeriodicalIF":0.8,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/ba/acc-09-02-69.PMC9262081.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9290710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Successful outcome using Tocilizumab in COVID-19 pneumonia with respiratory failure on a ward level","authors":"B. Morărașu, Aida Basirat, M. Kooblall, S. Lane","doi":"10.22551/2022.34.0901.10200","DOIUrl":"https://doi.org/10.22551/2022.34.0901.10200","url":null,"abstract":"Abstract We describe the case of a 40-year-old man of Asian ethnicity, who presented with one week history of shortness of breath, productive cough, intermittent hemoptysis, temperature, and systemic symptoms. He had a positive nasopharyngeal swab for SARS-CoV-2, standard COVID panel admission blood tests, a chest X-ray and a CT Pulmonary Angiogram. Significant bilateral infiltrates and no pulmonary embolism were identified. The patient received standard COVID-19 treatment. After 36 hours, he deteriorated requiring initiation of non-invasive ventilatory (NIV) support. In the context of worsening clinical status, the patient received Tocilizumab as a single dose with good clinical response. Early Tocilizumab intervention in appropriately selected patients should improve the outcome and length of hospitalization in COVID-19 pneumonia. It can be used as an intensive therapy unit sparing agent allowing management of critically ill patients on a ward-based level. This may further contribute to prevention of intensive therapy unit related complications and increased mortality.","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"9 1","pages":"29 - 33"},"PeriodicalIF":0.0,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45056994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Jiffry, M. Ahmed-khan, Felipe Carmona Pires, Nkechi A Okam, Mahnoor Hanif
{"title":"Diagnostic dilemma in a patient presenting with thrombotic microangiopathy in the setting of pregnancy","authors":"M. Jiffry, M. Ahmed-khan, Felipe Carmona Pires, Nkechi A Okam, Mahnoor Hanif","doi":"10.22551/2022.34.0901.10199","DOIUrl":"https://doi.org/10.22551/2022.34.0901.10199","url":null,"abstract":"Abstract We report a case of thrombotic microangiopathy in a postpartum female for which considerable diagnostic uncertainty existed initially regarding the etiology. This case highlights the limitations surrounding PLASMIC scoring criteria for the diagnosis of thrombotic thrombocytopenic purpura (TTP). A 32-year-old woman presented to maternofetal medicine in her third trimester of pregnancy at 32 weeks for a routine follow up and was subsequently found to have elevated blood pressures with proteinuria, and was diagnosed with pre-eclampsia. Worsening anemia and thrombocytopenia prompted a blood smear which showed schistocytes, concerning for a thrombotic microangiopathy. Creatinine was also elevated with normal liver enzymes being noted. A PLASMIC score of 4 placed her in the low-risk category for severe ADAMTS13 deficiency whilst she fulfilled criteria for partial HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome per Tennessee classification. Despite delivery, her symptoms persisted with subsequent ADAMTS13 assay confirming acquired TTP, subsequently requiring repeated plasmapheresis and rituximab to achieve disease control. Thrombotic microangiopathy remains a diagnostic challenge especially in the peripartum population, and scoring systems such as PLASMIC score and Tennessee classification may be of limited utility.","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"9 1","pages":"24 - 28"},"PeriodicalIF":0.0,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44999544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ioana-Codruța Lebădă, R. Ristea, M. Metiu, M. Stanciu
{"title":"Vitamin D deficiency in thyroid autoimmune diseases","authors":"Ioana-Codruța Lebădă, R. Ristea, M. Metiu, M. Stanciu","doi":"10.22551/2022.34.0901.10201","DOIUrl":"https://doi.org/10.22551/2022.34.0901.10201","url":null,"abstract":"Abstract The role of vitamin D in the human body is a complex one, proven by the many studies performed related to this aspect. Data from the literature on the correlation between vitamin D deficiency and thyroid autoimmune pathology, although present and increasing in the last 10 years, have failed to establish exactly whether or not there is a link between them. The aim of the study was to assess the status of vitamin D in patients with autoimmune thyroid disease; and to determine if there is a correlation between parameters such as: thyroid stimulating hormone (TSH), free thyroxine (FT4), ATPO; and vitamin D levels. Therefore, we performed a retrospective study in which we included 60 patients, 32 with autoimmune thyroid pathology and 28 patients with negative antithyroid antibodies. The average age of those in the case group was 58 years old and 52 years old for the control group. Female sex was predominant in both groups of patients, 97% in the study group and 71% in the control group. Vitamin D values in patients with thyroid autoimmune pathology in our study were on average higher than those obtained in the control group (patients with negative thyroid antibodies), without finding a statistically significant difference between the values of the two groups of patients (p = 0.197). The study shows a high prevalence of vitamin D deficiency in both groups of patients (with or without autoimmune thyroid disease), the highest rate being observed among patients without autoimmune pathology, but without a statistically significant difference between values.","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"9 1","pages":"34 - 40"},"PeriodicalIF":0.0,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44394876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Leptomeningeal carcinomatosis in gastric cancer: a case report of a rare yet aggressive entity","authors":"M. Baleiras, J. Graça, Leonor Fernandes","doi":"10.22551/2022.34.0901.10196","DOIUrl":"https://doi.org/10.22551/2022.34.0901.10196","url":null,"abstract":"Abstract Leptomeningeal carcinomatosis (LMC) is exceedingly rare in gastric cancer. It is most commonly seen in breast, lung cancer and melanoma, and is associated with an extremely poor prognosis. If untreated, median overall survival is four to six weeks. No standard treatment for LMC exists and published data are scarce. We present two cases of gastric carcinoma diagnosed with LMC that exemplify how aggressive this condition is and how short the time lapse is to perform any targeted therapy. This report aims to raise awareness of this rare metastatic possibility in gastric cancer and its diagnostic and therapeutic challenges.","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"9 1","pages":"6 - 11"},"PeriodicalIF":0.0,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49458687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New onset severe ulcerative colitis following Ixekizumab therapy.","authors":"Alina Mihaela Morosanu, Ioana Ruxandra Mihai, Ioana Irina Rezus, Otilia Gavrilescu, Mihaela Dranga, Cristina Cijevschi Prelipcean, Catalina Mihai","doi":"10.22551/2022.37.0904.10227","DOIUrl":"https://doi.org/10.22551/2022.37.0904.10227","url":null,"abstract":"<p><p>Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic arthritis. One week after first administration of Ixekizumab, she developed diffuse abdominal pain, bloody diarrhea (7-8 stools/day) and fever. Following imaging (colonoscopy, computed tomography) and laboratory investigations, she was diagnosed with acute severe ulcerative colitis complicated with toxic megacolon. The medical treatment (first corticotherapy, then infliximab) has failed and the patient needed emergency colectomy. Based on the immunological mechanisms and the observation from other studies, Ixekizumab should be considered an etiology for new-onset inflammatory bowel disease.</p>","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"9 4","pages":"173-176"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/56/acc-09-04-173.PMC9769074.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10511186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination.","authors":"Hamidreza Zaheri, Arda Kiani, Siamak Afaghi, Fatemehsadat Rahimi, Mohammadhossein Banitorfi, Amirmohammad Kazemzadeh Norozi, Samaneh Hashemi, Atefeh Abedini","doi":"10.22551/2022.37.0904.10222","DOIUrl":"https://doi.org/10.22551/2022.37.0904.10222","url":null,"abstract":"<p><p>The global COVID-19 vaccination had an undeniable influence on the pandemic management, despite of having reported rare but life-threatening side-effects of vaccines. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune complication determined by thrombocytopenia and thrombosis propensity in the circulatory system. The activation of antibodies against platelet factor-4 (PF-4) which mimics the heparin-induced thrombocytopenia (HIT) characteristic is the main known pathogenicity of the disease. Herein, we reported a case of VITT in a middle-aged woman with no previous history of thrombophilia or other medical conditions who presented with thrombosis of the left superficial femoral artery 3-days after receiving the second dose of inactivated BBIBP-CorV (Sinopharm) vaccine. The patient underwent bypass vascular surgery and received none-heparin anticoagulation consistent with high-dose intravenous immunoglobin. Eight days after the discharge, she was subsequently referred to our center with the presentation of sub-massive pulmonary thromboembolism in spite of receiving the prophylactic anticoagulants during follow-up period. Details on side-effects of COVID-19 vaccines, specifically the inactivated ones are yet to be fully ascertained. Clinicians should consider the history of COVID-19 vaccines in thromboembolism patients who do not have well-acknowledged risk factors. Further studies about the necessity of prophylactic anticoagulants and clinical judgment for receiving other vaccines in such patients are required.</p>","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"9 4","pages":"150-153"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/f4/acc-09-04-150.PMC9769072.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10511193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hypoxic ischemic brain injury with status myoclonus in a case with post-operative massive pulmonary thromboembolism: A diagnostic and therapeutic challenge.","authors":"Ritwick Mondal, Somesh Saha, Shramana Deb, Rahul Jain, Arindam Maitra, Manoj Mahata","doi":"10.22551/2022.37.0904.10225","DOIUrl":"https://doi.org/10.22551/2022.37.0904.10225","url":null,"abstract":"<p><p>Thromboembolic event is an important and widely regarded risk factor, influencing the outcome and overall survival in post-operative cases with second highest association with gynaecological surgeries. Here we report a 52 years old female who underwent total laparoscopic hysterectomy with bilateral salpingo-oophorectomy (TLH+BSO) presented to our emergency in unconscious and intubated state on her post-operative day-1 with cardiorespiratory failure. Based on the immediate investigations after successful resuscitation, an initial diagnosis of massive pulmonary thromboembolism was made following supportive and conservative management. Interestingly on subsequent days she started to display episodic non-rhythmic symmetric myoclonic jerks persisting for seconds to minutes; resembling 'post-hypoxic' or 'post-anoxic' status myoclonus due to hypoxic ischemic brain injury. Further neuro-electrophysiological examination revealed rhythmic well-formed delta activity on both sides symmetrically with a transformation into theta activity with forward displacement on subsequent days, bilaterally over the same areas. Later on, magnetic resonance imaging with magnetic resonance-spectroscopic findings also corroborated to hypoxic ischemic brain injury related changes over bilateral basal ganglia mostly in caudate nucleus. Post operative venous thromboembolism is a major clinical challenge and a subject of constant intensive care yet the neurological sequalae of such event is given less priority despite of its major contribution on overall prognostic and survival index.</p>","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"9 4","pages":"161-169"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/22/acc-09-04-161.PMC9769078.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10870320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}